Burya, L. V.Vakhnenko, A. V.Moiseieva, N. V.Kapustianska, A. A.Zviagolska, I. M.Буря, Лілія ВолодимирівнаВахненко, Андрій ВікторовичМоісєєва, Наталія ВіталіївнаКапустянська, Анна АнатоліївнаЗвягольська, Ірина МиколаївнаБуря, Лилия ВладимировнаВахненко, Андрей ВикторовичМоисеева, Наталья ВитальевнаКапустянская, Анна АнатольевнаЗвягольская, Ирина Николаевна2020-12-302020-12-302020Current strategy for treatment of comorbid states: complicated community-acguired pneumonia with arterial hypertension / L. V. Byrya, A. V. Vakhnenko, N. V. Moisieva [et al.] // Wiadomosci Lekarskie. – 2020. – V. LXXIII, is. 6. – P. 1057–1260.https://repository.pdmu.edu.ua/handle/123456789/14489The aim: To optimize the treatment of CAP patients with hypertension, complicated by exudative pleuritis. Materials and methods: The study included 43 CAP patients, aged 46 to 65 years, with viral lesions along with hypertension. The average age of the patients was 52.5 ± 4.5 years. Veri cation of the CAP diagnosis and its formulation was performed in accordance with the order of the Ministry of Health of Ukraine No. 128 of 19.03.2007 “On the approval of clinical protocols of medical care in “Pulmonology” in all patients, pneumonia was complicated by exudative pleuritis, which was con rmed by X-ray examination. Results: The use of combination drugs, namely, torasemide with prolonged e ect and tivortin aspartate in the treatment of patients with community-acquired pneumonia, complicated by exudative pleuritis, combined with hypertension led to more signi cant positive changes in the values of saturation, blood biochemical parameters, as well as accelerated recovery of patients, which was con rmed by the positive dynamics of X-ray examination. Conclusions: As a result of the treatment, all parameters of the quality of life of the patients were greatly improved, which resulted in a signi cant reduction in functional limitations and high social activity of the patients, which signi cantly reduced the cost of treatment.encommunity-acquired pneumoniaexudative pleuritishypertensionL-argininetorasemideArticle10.36740/WLek202006134